Federal: HR4837

Bill Summary

US HR 4837, the Written Informed Consent Act, directs the Secretary of Veterans Affairs to expand Veterans Health Administration Directive 1005 to require comprehensive written informed consent for five medication categories beyond opioids: antipsychotics, stimulants, antidepressants, anxiolytics, and narcotics. Veterans would receive detailed information about potential risks and benefits of these medications before being prescribed them. The bill strengthens patient communication and safety protocols in veterans' healthcare by ensuring explicit patient understanding and consent before treatment begins. Currently, detailed informed consent protocols apply primarily to long-term opioid therapy, leaving other powerful medications with less rigorous patient disclosure requirements.

Why It Matters to MAHA

This bill directly advances MAHA's core principle of patient autonomy and informed consent by ensuring veterans have complete transparency about the medications they are prescribed. Expanding informed consent requirements removes barriers to true patient choice by guaranteeing that individuals understand the risks, benefits, and alternatives before accepting treatment. Many veterans report being prescribed psychotropic and pain medications without adequate discussion of side effects, dependency risks, or alternative therapies, undermining their ability to make autonomous health decisions. By requiring written informed consent for these medication classes, the bill empowers veterans to participate meaningfully in their own healthcare and reduces the likelihood of unwanted or inadequately explained pharmaceutical interventions. This represents health freedom in action: patients informed, aware, and in control of medical decisions affecting their bodies.